GSK plc × Noetik, Inc.
GSK and Noetik announced a five-year collaboration in which GSK will license Noetik's AI foundation models for cancer research. The deal includes a $50 million upfront payment and near-term milestones, along with annual licensing fees for access to updated models. GSK gains a non-exclusive license to Noetik's 'OCTO-VC' model, which was trained on Noetik's proprietary spatial biology dataset of hundreds of millions of cells.
The asset
A non-exclusive license to Noetik's 'OCTO-VC' foundation models, trained on a proprietary spatial biology dataset, for use in cancer research.
The record
- Seller status
- Going concern
- Sector
- AI drug discovery
- Modalities
- scientific_data
What it means if you hold data
This deal exemplifies a growing trend of pharmaceutical companies licensing specialized, pre-trained AI foundation models to accelerate drug discovery. It highlights how proprietary, high-quality datasets (in this case, spatial biology data) are becoming critical assets for creating valuable AI models in specialized fields like oncology.